VEGFA and hepatocellular carcinoma: An FDA-approved first-line therapy for advanced HCC is a combination of atezolizumab and bevacizumab, which employs an immune checkpoint programmed death-ligand 1 (PD-L1) inhibitor and an inhibitor of vascular endothelial growth factor (VEGF), respectively.